Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "International-Congress-of-Parkinson's-Disease-and-Movement-Disorders"

2 News Found

Zydus to present on ZYIL1 at the International Congress of Parkinson's Disease and Movement Disorders
Diagnostic Center | August 28, 2023

Zydus to present on ZYIL1 at the International Congress of Parkinson's Disease and Movement Disorders

In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers


BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint
Diagnostic Center | August 29, 2023

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year